Modalities | Settings | Advantages | Limits | Indications |
---|---|---|---|---|
O2 mask | Oxygen flow: adjust with objective of SaO2 92–98% | Avoid hypoxia Simple and accessible device | No PEEP effect Limited oxygen flow at 15 L/min | First-line support until NIV or IMV in case of respiratory failure Acute cardiogenic pulmonary edema: compared to oxygenotherapy, PEEP induced a faster improvement of respiratory distress and acidosis without significant difference in mortality or intubation within 7 days [109] No data regarding CS specifically |
Non invasive ventilation (NIV) Continuous positive airway pressure (CPAP) Bilevel positive air pressure (BIPAP) | Positive Pressure ventilation (PPV) with positive end expiratory pressure (PEEP): minimal starting setting at 5–10 cmH2O, adjust according to SaO2 In case of BIPAP, adjust inspiratory positive airway pressure according to respiratory rate FiO2: adjust with objective of SaO2 92–98% [106] Need correct selection of interfaces, favorable patient/ventilator synchrony, comfort and active participation of the patient | 1. Respiratory effects: Reduced alveolo-interstitial edema Induced alveolar recruitment Improve oxygenation: reversion of hypoxic pulmonary vasoconstriction, better systemic and myocardial oxygenation Improve decarboxylation Decreasing work-of-breathing and reduce the oxygen consumption of the diaphragm 2. Hemodynamic effects Reduce RV/LV preload and LV afterload Improve cardiac output Could reduce the risk of invasive mechanical ventilation [111,112,113] Simple and accessible device | Absolute contraindications: Severely impaired consciousness Refractory vomiting Facial trauma Hemodynamic instability Relative contraindications: Inability to cough Uncooperative patient NIV compared to IMV in a non-randomized study: no difference of mortality [115] | First line: respiratory distress in heart failure patients, without absolute contraindications to NIV [5, 34, 35, 106] Second line: should be considered in CS only after: Hemodynamic stabilization An assessment of the risk–benefit balance Without absolute contraindications to NIV With a close monitoring of efficacity Device: BIPAP increase Vt and could be preferable compared to CPAP in case of hypercapnia, chronic lung disease or severe RF |
Invasive mechanical ventilation (IMV) | FiO2: adjust with objective of SaO2 92–98% [106] PEEP: set at 5 cmH2O, gradually increased according to respiratory (overdistension, barotrauma) and hemodynamic (decrease RV preload and increase RV afterload) risks of excessive PEEP Respiratory rate: adjust to limit hypercapnia acidosis (worsening of RV dysfunction risk) Vt: should not exceed 6–8 mL/kg of ideal body weight No data and recommendations regarding superiority of any specific mode (volume or pressure control) [5, 34, 35, 106] | 1. Respiratory effects: Reduced alveolo-interstitial edema Induced alveolar recruitment Improve oxygenation: reversion of hypoxic pulmonary vasoconstriction, better systemic and myocardial oxygenation Improve decarboxylation Decreasing work-of-breathing and reduce the oxygen consumption of the diaphragm 2. Hemodynamic effects: Reduce RV/LV preload and LV afterload Improve cardiac output Sedation use: could reduce oxygen consumption and improve cardiac output | Risks associated with anaesthesia induction and intubation: hypotension, hypoxia, transient low cardiac output due to intrathoracic pressures change, cardiac arrest Specific mode: pressure supported ventilation (PSV) could increase myocardial oxygen consumption if spontaneous breath is no fully supported [122] | Refractory shock with severe hypotension Need for effective airway protection due to coma/impairment of consciousness Refractory vomiting Facial trauma |
High flow nasal canula (HFNC) | FiO2: adjust with objective of SaO2 92–98% | High oxygen flow (max 60L/min, FIO2 1) Improvement of oxygenation Simple and accessible device | Inconstant PEEP “effect”, between 5 and 7 cmH2O | Scarce data |